|Bid||0.00 x 1000|
|Ask||0.00 x 1200|
|Day's Range||143.05 - 146.79|
|52 Week Range||101.07 - 179.65|
|Beta (3Y Monthly)||2.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||178.33|
To be honest, I’m not entirely thrilled about investing in marijuana stocks at the moment. Initial products such as Epidiolex and Sativex are used to treat epilepsy and spasticity caused by multiple sclerosis.
HENDERSON, NV / ACCESSWIRE / October 15, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
One of the hottest areas in the investment world today is legal cannabis. Although marijuana and related products are not fully legal across the United States, the move by individual states to legalize cannabis for medical or, in some cases, recreational use has opened up many avenues for potential investment opportunities. GW Pharmaceuticals PLC ADR ( GWPH) is a biopharmaceutical company headquartered in the U.K. GW aims to develop products within the medical cannabis portion of the legal marijuana industry.
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Molson Coors became the latest major beverage company to announce plans to start their own CBD beverage arm. Coca-Cola and InBev have also announced similar ...
If you're interested in profiting from the marijuana movement, you might want to consider owning a marijuana exchange-traded fund.
In market-related news, shares of Tilray Inc (NASDAQ: TLRY) tumbled Tuesday, after beverage giant PepsiCo, Inc. (NASDAQ: PEP) put an end to speculation about a potential entry into the cannabis space. “I think the difficulties in investing in that category, particularly in the U.S., where federally these things are still not legal, are quite a considerable challenge,” PepsiCo Chief Financial Officer Hugh Johnston said on a company call. GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) said it was issuing 1.9 million ADSs in a bid to raise $300 million.
GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.
According to New Age Beverages (NASDAQ:NBEV) CEO Brent Willis, the company is preparing to show off its new line of CBD drinks next week. While that’s good news for New Age Beverages stock, it isn’t the major launch that some investors may be hoping for. Instead, the company is still talking to retailers about selling the drinks in states where they are legal.
GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.
Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / One of the major reasons cannabis stocks are doing so well is because they are potential solutions to long standing challenges, such as the opioid epidemic. ...
GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Boston Scientific Corporation (NYSE: BSX ) Eli Lilly ...
GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company.
Stock futures: Hot IPO Stitch Fix earnings topped, but other metrics missed. Stitch Fix stock dived. Marijuana plays New Age Beverages, India Globalization and DavidsTea were volatile.
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The DEA has just made a move that makes that has investors fired up.Last week, U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval. The agency announced Thursday that drugs including "finished dosage formulations" of CBD with THC below 0.1% will be considered Schedule 5 drugs, as long as the medications have been approved by the U.S. Food and Drug Administration. This has made CBD stocks even hotter than they have been.CBD stallwarts like GW Pharma, who was a large reason for this ruling are obviously benefitting, however, for investors looking to maximize their profit potential from this ruling it's beneficial to dig a little deeper.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...
GW Pharmaceuticals PLC said late Monday that it plans to sell $300 million worth of American depositary shares. Shares in the company fell 1.6% after hours. GW is a U.K.-based pharmaceutical company that seeks to make products with cannabis. The underwriters have an option to buy $45 million more shares within 30 days. Goldman Sachs, Morgan Stanley, J.P. Morgan and Cowen and Company are acting as joint book-running managers for the offering. GW stock closed down 3.3% to $167.10 in Monday trading. GW stock has gained 27% this year as the S&P 500 index rose 9.4%.
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform and whose U.S. subsidiary is Greenwich Biosciences, announced today that it intends to sell, subject to market and other conditions, $300 million of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the Nasdaq Global Market in an underwritten U.S. public offering. GW expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.